Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Endometrial Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Breast Neoplasms 4 Prostatic Neoplasms 3 Lung Neoplasms 3 Leukemia, Myeloid, Acute 3 Urinary Bladder Neoplasms 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leukemia 2 Colonic Neoplasms 2 Carcinoma, Intraductal, Noninfiltrating 2 Vulvar Neoplasms 1 Uterine Cervical Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Smoldering Multiple Myeloma 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Retinoblastoma 1 Peritoneal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Oropharyngeal Neoplasms 1 Neuroblastoma 1 Neoplasms 1 Mouth Neoplasms 1

Interventions

Specimen Handling 5 Nivolumab 4 avelumab 3 Magnetic Resonance Spectroscopy 3 pembrolizumab 2 cabozantinib 2 atezolizumab 2 Ipilimumab 2 Immunoglobulin G 2 Disulfides 2 CTLA-4 Antigen 2 Biopsy 2 tremelimumab 1 tocilizumab 1 relatlimab 1 guadecitabine 1 eribulin 1 erdafitinib 1 enfortumab vedotin 1 durvalumab 1 Watchful Waiting 1 Propranolol 1 Observation 1 Gemcitabine 1 Doxorubicin 1 Cystoscopy 1 Contrast Media 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Ureteral Neoplasms × Observation × Clear all

NCT03244384 2026-05-29

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡